Sartorius Stedim Biotech completes acquisition of Novaseps chromatography division

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the US Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 employees work at the Pompey site in eastern France and some in the USA, China, and India. The portfolio acquired comprises chromatography systems primarily suited for smaller biomolecules, such as oligonucleotides, peptides, and insulin, as well as innovative systems for continuous manufacturing of biologics. Since 2018, Novasep and Sartorius Stedim Biotech have also been jointly developing optimized systems for a membrane-based chromatography technology. As the acquisition is expected to generate additional non-organic sales revenue growth of around 1 percentage point in 2022, Sartorius Stedim Biotech has updated its sales revenue forecast for the current year as follows: Consolidated sales revenue is now expected to increase by about 15 per cent to 19 per cent (previously about 14 per cent to 18 per cent), with non-organic growth from acquisitions projected to contribute about 2 percentage points (previously about 1 percentage point). The company

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!